Drugs / 4'-iodo-4'-deoxydoxorubicin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00030381 | Dec 2001 → Jan 2003 | primary systemic amyloidosis | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00003853 | Apr 1999 → Aug 2000 | plasma cell neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4'-iodo-4'-deoxydoxorubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003853 ↗ |
| Known as | IDOX | “4'-Iodo-4'-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits.” PMID 12000194 ↗ Mar 2002 |
| Route | Intravenous | “IDOX was administered intravenously over 1 hour” PMID 12000194 ↗ Mar 2002 |